Ask AI
ProCE Banner Activity

Managing Adverse Events With Targeted Agents in CLL/SLL

Slideset

These downloadable slides highlight adverse events associated with targeted therapies currently used to manage CLL/SLL and recommended mitigation strategies.

Released: December 04, 2025

Share

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Lilly.

AstraZeneca

Lilly

Partners

Clinical Care Options, LLC

ProCE Banner

Target Audience

This educational activity is intended for hematologists, medical oncologists, physician associates, nurses, pharmacists, and other healthcare professionals who care for patients with chronic lymphocytic leukemia / small lymphocytic lymphoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select individualized frontline therapy for patients with CLL/SLL, based on current evidence, recommendations outlined in NCCN Guidelines, expert guidance, and patient medical history and preferences

  • Plan optimal treatment strategies for patients with R/R CLL that integrate recommendations outlined in the NCCN Guidelines, emerging targeted therapy approaches, sequencing therapy based on response to and tolerance of prior therapy, and mechanisms of resistance

  • Devise comprehensive patient education and supportive care strategies for targeted therapy–associated AEs to improve clinical outcomes